Back to compounds

COMPOUND PROFILE / PEPTIDES & ANALOGUES

VK2735.

Research draft

VK2735 is a dual GIP and GLP-1 receptor agonist investigated for obesity.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Overview

VK2735 is a dual GIP and GLP-1 receptor agonist investigated for obesity.

CLASSIFICATIONPeptides & analogues
MOLECULAR / SEQUENCE INFONot specified
PRIMARY CONTEXTCompound

Mechanism

It combines incretin pathways affecting appetite and glucose regulation.

Human research

The randomised subcutaneous VENTURE study provides phase 2 evidence. Oral formulation development must be assessed separately.

Preclinical & other research

Receptor and metabolic studies informed development.

Safety & unknowns

Gastrointestinal symptoms and limited long-term exposure are relevant.

Regulatory status

Investigational; oral and injectable versions are not interchangeable evidence.

Reported use & evidence

Research profile draft

The supplied VK2735 profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Explore more compounds